{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:40:38Z","timestamp":1770914438085,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: In order to support the positioning of Rho kinase inhibitors (Rhokis) in the European market for the treatment of glaucoma, scientific evidence comparing the efficacy and safety of Rhokis and beta-blockers (\u03b2-\u03b2s) in the treatment of open-angle glaucoma after 3 months was assembled through a systematic review and meta-analysis (meta-A) of randomized controlled trials (RCTs). Methods: Relevant articles were searched for on PubMed, EMBASE, and the Cochrane Library. Of the 251 articles found, three met all eligibility criteria. These three articles were assessed for risk of bias. Data were extracted and a random effects meta-A was performed. The studies\u2019 methods were homogeneous but there was great heterogeneity within the data (I2 = 92\u201393%; p &lt; 0.001). Results: All studies had low risk of bias. The meta-A showed statistically better efficacy of \u03b2-\u03b2s, resulting in an intraocular pressure (IOP) reduction mean difference of 1.73 (1.19\u20132.27) at 8 a.m., 0.66 (0.19\u20131.15) at 10 a.m. and 0.49 mmHg (0.001\u20130.98) at 4 p.m., compared to Rhokis. This difference is not clinically significant as intra-operator variability of IOP measurements varies from \u00b12 to \u00b13 mmHg The adverse effects of Rhokis were essentially topical, whereas \u03b2-\u03b2s mainly caused systemic side effects. Conclusions: This Meta-A showed that Rhokis are clinically non-inferior to beta-blockers in reducing IOP. Rhokis have a better safety profile.<\/jats:p>","DOI":"10.3390\/jcm13061747","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:17:29Z","timestamp":1710749849000},"page":"1747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Rho Kinase Inhibitors vs. Beta-Blockers in Primary Open-Angle Glaucoma: A Systematic Review with Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"given":"Brenda","family":"Nana Wandji","sequence":"first","affiliation":[{"name":"H\u00f4pital Universitaire de Bruxelles (HUB), CUB H\u00f4pital Erasme, Service d\u2019Ophtalmologie, Universit\u00e9 Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Bruxelles, Belgium"},{"name":"Ecole de Sant\u00e9 Publique, Universit\u00e9 Libre de Bruxelles, 1070 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9lie","family":"Bacq","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire de Bruxelles (HUB), CUB H\u00f4pital Erasme, Service d\u2019Ophtalmologie, Universit\u00e9 Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6796-2779","authenticated-orcid":false,"given":"Ad\u00e8le","family":"Ehongo","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire de Bruxelles (HUB), CUB H\u00f4pital Erasme, Service d\u2019Ophtalmologie, Universit\u00e9 Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.mcna.2021.01.004","article-title":"Glaucoma","volume":"105","author":"Kang","year":"2021","journal-title":"Med. Clin. N. Am."},{"key":"ref_3","first-page":"e11686","article-title":"Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future","volume":"12","author":"Allison","year":"2020","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: A systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/IJG.0000000000002083","article-title":"Primary Open Angle Glaucoma Prevalence in Europe: A Systematic Review and Meta-Analysis","volume":"31","author":"Aiello","year":"2022","journal-title":"J. Glaucoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: A review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2165\/00002512-199711050-00003","article-title":"Systemic adverse effects of topical ophthalmic agents. Implications for older patients","volume":"11","author":"Diamond","year":"1997","journal-title":"Drugs Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.17116\/oftalma2020136062155","article-title":"Development of additive systemic effects when taking \u03b2-blockers in patients with glaucoma and concurrent chronic diseases","volume":"136","author":"Filimonova","year":"2020","journal-title":"Vestn. Oftalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2169\/internalmedicine.5598-20","article-title":"Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease","volume":"60","author":"Arai","year":"2021","journal-title":"Intern. Med."},{"key":"ref_13","first-page":"CD013817","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","volume":"6","author":"Kolko","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.2174\/0929867325666181031102829","article-title":"Rho-kinase (ROCK) Inhibitors\u2014A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility","volume":"27","author":"Abbhi","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-021-05379-7","article-title":"Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: A meta-analysis and systematic review of prospective randomized trials","volume":"260","author":"Wu","year":"2022","journal-title":"Graefe Arch. Clin. Exp. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","article-title":"Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma","volume":"26","author":"Sturdivant","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00347-020-01303-2","article-title":"Rho kinase inhibitors as new local therapy option in primary open angle glaucoma","volume":"118","author":"Erb","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2147\/OPTH.S318897","article-title":"Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma","volume":"15","author":"Naik","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bcp.13006","article-title":"Respiratory effect of beta-blocker eye drops in asthma: Population-based study and meta-analysis of clinical trials","volume":"82","author":"Morales","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajem.2020.09.082","article-title":"Cardiac and extracardiac side effects of eye drops","volume":"46","author":"Jolobe","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263.e5","DOI":"10.1016\/j.ajem.2020.09.030","article-title":"Ocular timolol as the causative agent for symptomatic bradycardia in an 89-year-old female","volume":"42","author":"Rains","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients with Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients with Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study","volume":"204","author":"Khouri","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","first-page":"599","article-title":"An update on ripasudil for the treatment of glaucoma and ocular hypertension","volume":"56","author":"Testa","year":"2020","journal-title":"Drugs Today Barc. Spain 1998"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ottobelli, L., Fogagnolo, P., Frezzotti, P., De Cill\u00e0, S., Vallenzasca, E., Digiuni, M., Paderni, R., Motolese, I., Bagaglia, S.A., and Motolese, E. (2015). Repeatability and reproducibility of applanation resonance tonometry: A cross-sectional study. BMC Ophthalmol., 15.","DOI":"10.1186\/s12886-015-0028-9"},{"key":"ref_29","first-page":"138","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition","volume":"105","author":"Spaeth","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined with Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3341\/kjo.2022.0061","article-title":"Comparison of Netarsudil\/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis","volume":"36","author":"Lee","year":"2022","journal-title":"Korean J. Ophthalmol. KJO"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-018-0877-7","article-title":"Netarsudil Ophthalmic Solution 0.02%: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials","volume":"112","author":"Webers","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/jop.2005.21.388","article-title":"The Efficacy of Timolol in Gel-Forming Solution After Morning or Evening Dosing in Asian Glaucomatous Patients","volume":"21","author":"Ong","year":"2005","journal-title":"J. Ocul. Pharmacol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:15:24Z","timestamp":1760105724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061747"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061747","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}